IRCT20200407046981N21招募中未知
Comparative bioequivalence study of the Rosuvastatin 20-mg tablet manufactured by Daana Pharmaceutical Company versus Crestor® (AstraZeneca Company).
Daana pharmaceutical company0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- Male
入选标准
- •The weight limit of each volunteer should be between 60 and 100 kg.
- •All volunteers must be non-smokers.
- •They must be healthy in terms of liver, kidney, respiratory system, mental and other general health characteristics that will be assessed.
- •Candidates who have consented to the consent form.
排除标准
- •Known hypersensitivity or idiosyncratic reaction to Rosuvastatin or any ingredients.
- •Subjects with BP = 90/60 mm/Hg or BP = 140/90 mm/Hg.
- •Regular smoker who smokes more than ten cigarettes daily.
- •Taking any medicine during two weeks before dosing.
研究者
相似试验
已完成
不适用
Bioequivalence study of Rosuvastatin 40 mg tablet in 24 healthy male under fasting conditionsIRCT20180620040164N25Karen Pharma and Food Supplement Co.24
招募中
不适用
Bioequivalence study of Rosuvastatin 40 mg tablet in 24 healthy male under fasting conditionsIRCT20180620040164N22Dorsa Pharmaceutical Co.24
尚未招募
不适用
Study of absorption and elimination rate of Atorvastatin 80-mg/Ezetimibe 10-mg tablet (Lipzib®) in comparison with Atorvastatin 80-mg/Ezetimibe 10-mg brand tablet (Liptruzit®)IRCT20200407046981N34ikasa Pharmed Pharmaceutical Company24
尚未招募
不适用
In-vivo Bioequivalence Test of Rosuvastatin tablets with brand name drug CRESTOR® 20mg F.C Tab. Made by ASTRA-Zeneca, UK in Iranian healthy volunteers.IRCT20200105046010N11Tabriz University of Medical Sciences24
招募中
不适用
In-vivo Bioequivalence Test of Rosuvastatin tablets with brand drug (CRESTOR® 20mg F.C Tab, AstraZeneca, Belgium)IRCT20200105046010N41Kharazmi Pharmaceutical Co24